HOME > COMMENTARY

COMMENTARY

Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (2)

June 27, 2005
Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (1)

June 20, 2005
Special Contribution

May 16, 2005
Japan's Most Admired Pharma Companies P. Reed Maurer President, NPP

April 18, 2005
PRTM Shows Results of Investigational Drug Survey

March 14, 2005
＜Special Comtribution＞

March 7, 2005
＜Special Comtribution＞

March 7, 2005
JPMA Update (12)

November 22, 2004
JPMA Pudate(11)

November 15, 2004
JPMA Update (10)

November 8, 2004
JPMA Update (9)

November 1, 2004
JPMA Update (8)

October 25, 2004
JPMA Update (7)

October 18, 2004
JPMA Update (6)

October 11, 2004
＜Special Contribution＞

October 4, 2004
JPMA Update (5)

October 4, 2004
JPMA Update(4)

September 27, 2004
JPMA Update (3)

September 20, 2004
JPMA Update (2)

September 13, 2004
＜New Series＞

September 6, 2004

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…